Roumen Balabanov to Treatment Outcome
This is a "connection" page, showing publications Roumen Balabanov has written about Treatment Outcome.
Connection Strength
0.024
-
Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study. Adv Ther. 2021 07; 38(7):3724-3742.
Score: 0.024
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.